CME Group (CME) 47th Annual Raymond James Institutional Investor Conference summary
Event summary combining transcript, slides, and related documents.
47th Annual Raymond James Institutional Investor Conference summary
3 Mar, 2026Market overview and business model
Operates as the world's leading derivatives exchange with a dual mandate: price transparency and risk management.
Offers benchmark products across all major asset classes: fixed income, equities, FX, energy, metals, agriculture, and crypto.
Runs a vertically integrated clearinghouse, creating high barriers to entry and defensible business model.
Strategic technology partnership with Google to enhance cloud capabilities and global reach.
Proprietary data business generated $800 million in revenue, growing at 8–13% annually.
Financial performance and growth
Achieved 6% growth in both volumes and revenues over the past year, with record average daily volume (ADV) of 28.1 million contracts.
Adjusted operating margin reached 69.4%, reflecting strong expense discipline and scalable model.
Non-transactional revenues totaled $1.7 billion, with market data and interest income as key contributors.
Year-to-date ADV is 35.5 million contracts, up 16%, with 45 million contracts traded on peak days.
Multi-year growth in adjusted net income at 12% CAGR, supporting robust capital return policy.
Globalization and client diversification
Non-US business is growing at 10% annually, outpacing US growth and contributing higher margins.
Majority of sales force now based in London, with significant expansion in Europe, Asia Pacific, and LATAM.
47% of FX and metals trading volume comes from outside the US, with commodities leading non-US participation.
Retail client base expanding rapidly, especially through micro contracts and partnerships with brokers like Robinhood and tastytrade.
45% of retail business originates from non-US clients, adding high-margin, net new customers.
Latest events from CME Group
- Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Record 2025 growth fueled by innovation, global reach, and strong capital efficiencies.CME
Investor presentation3 Mar 2026 - Record revenue, earnings, and trading volumes in 2025, with strong capital returns.CME
Q4 20254 Feb 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026 - Record Q2 revenue, net income, and trading volumes, with growth in every asset class and strong margins.CME
Q2 20243 Feb 2026 - Strong volumes and global uncertainty drive growth focus in equities and credit, with regulatory vigilance.CME
Piper Sandler Global Exchange and Trading Conference 20241 Feb 2026